Importer of Controlled Substances; Notice of Registration; Fisher Clinical Services, Inc., 1889 [2014-00179]
Download as PDF
<![CDATA[
1889
Federal Register / Vol. 79, No. 7 / Friday, January 10, 2014 / Notices
Drug
Schedule
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Morphine (9300) ...........................
Oxymorphone (9652) ...................
Remifentanil (9739) ......................
Fentanyl (9801) ............................
II
II
II
II
II
II
II
II
II
II
II
II
Drug
The company plans to import the
listed controlled substances in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically-manufactured FDF. This
analysis is required to allow the
company to export domesticallymanufactured FDF to foreign markets.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Mylan Pharmaceuticals, Inc., to import
the basic classes of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Mylan Pharmaceuticals, Inc., to ensure
that the company’s registration is
consistent with the public interest.
The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: December 31, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–00206 Filed 1–9–14; 8:45 am]
Schedule
Methyphendiate (1724) ................
Levorphanol (9220) ......................
Noroxymorphone (9668) ..............
Tapentadol (9780) ........................
II
II
II
II
The company plans to import the
listed controlled substances for clinical
trials, analytical research and testing.
The import of the above listed basic
classes of controlled substances will be
granted only for analytical testing and
clinical trials. This authorization does
not extend to the import of a finished
FDA approved or non-approved dosage
form for commercial distribution in the
United States.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Fisher Clinical Services, Inc., to import
the basic classes of controlled
substances is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Fisher Clinical Services, Inc., to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: December 31, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
mstockstill on DSK4VPTVN1PROD with NOTICES
on September 25, 2013, 78 FR 59064,
Fisher Clinical Services, Inc., 7554
Schantz Road, Allentown, Pennsylvania
18106, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the following basic classes of controlled
substances:
Drug Enforcement Administration
[FR Doc. 2014–00179 Filed 1–9–14; 8:45 am]
Importer of Controlled Substances;
Notice of Registration; Fisher Clinical
Services, Inc.
BILLING CODE 4410–09–P
By Notice dated September 16, 2013,
and published in the Federal Register
VerDate Mar<15>2010
16:40 Jan 09, 2014
Jkt 232001
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Cayman Chemical Company
Pursuant to 21 CFR 1301.33(a), this is
notice that on June 27, 2013, Cayman
Chemical Company, 1180 East Ellsworth
Road, Ann Arbor, Michigan 48108,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Cathinone (1235) ..........................
Methcathinone (1237) ..................
4-Methyl-N-methylcathinone
(1248).
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
Aminorex (1585) ...........................
4-Methylaminorex (cis isomer)
(1590).
Gamma
Hydroxybutyric
Acid
(2010).
JWH–250 (6250) ..........................
SR–18 also known as RCS–8
(7008).
XLR11 (7011) ...............................
JWH–019 (7019) ..........................
AKB48 (7048) ...............................
JWH–081 (7081) ..........................
SR–19 also known as RCS–4
(7104).
1-Pentyl-3-(1-naphthoyl)indole
(7118).
JWH–122 (7122) ..........................
UR–144 (7144) .............................
1-Butyl-3-(1-naphthoyl)indole
(7173).
1-[2-(4-Morpholinyl)ethyl]-3- .........
(1-naphthoyl) indole (7200) ..........
AM–2201 (7201) ...........................
JWH–203 (7203) ..........................
Alpha-ethyltryptamine (7249) .......
5-(1,1-Dimethylheptyl)-2-[(1R,3S)3-hydroxycyclohexyl]-phenol
(7297).
5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl]-phenol
(7298).
Lysergic acid diethylamide (7315)
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
2C–T–2 (7385) .............................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
E:\FR\FM\10JAN1.SGM
10JAN1
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
]]>Agencies
[Federal Register Volume 79, Number 7 (Friday, January 10, 2014)]
[Notices]
[Page 1889]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-00179]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration; Fisher
Clinical Services, Inc.
By Notice dated September 16, 2013, and published in the Federal
Register on September 25, 2013, 78 FR 59064, Fisher Clinical Services,
Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as an importer of the following basic classes of
controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Methyphendiate (1724)...................... II
Levorphanol (9220)......................... II
Noroxymorphone (9668)...................... II
Tapentadol (9780).......................... II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
clinical trials, analytical research and testing.
The import of the above listed basic classes of controlled
substances will be granted only for analytical testing and clinical
trials. This authorization does not extend to the import of a finished
FDA approved or non-approved dosage form for commercial distribution in
the United States.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a), and determined that the
registration of Fisher Clinical Services, Inc., to import the basic
classes of controlled substances is consistent with the public
interest, and with United States obligations under international
treaties, conventions, or protocols in effect on May 1, 1971. DEA has
investigated Fisher Clinical Services, Inc., to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the above named company is granted
registration as an importer of the basic classes of controlled
substances listed.
Dated: December 31, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2014-00179 Filed 1-9-14; 8:45 am]
BILLING CODE 4410-09-P
